企業概要
LifeStance Health Group, Inc. operates within the healthcare sector, specifically focusing on the medical care facilities industry, where it delivers essential outpatient mental health services to children, adolescents, adults, and geriatrics across the United States. The firm provides a comprehensive multidisciplinary suite of mental health services, encompassing psychiatric evaluations, clinical treatment, and psychological support for a diverse patient demographic. This business model positions the company as a specialized provider within the broader healthcare infrastructure, addressing critical mental wellness needs in the domestic market. As of the latest data, the enterprise maintains a market capitalization of $2.48B and generates annual revenue of $1.42B, supported by an employee base of 10,961 individuals. These valuation and revenue figures indicate a significant operational footprint within the niche mental health sector, suggesting the company has achieved substantial scale relative to peer groups in medical care facilities while maintaining a substantial workforce dedicated to patient care.
財務健全性
The company reported a trailing twelve-month revenue of $1.42B, with a corresponding net income of $9.66M and an EBITDA of $79.92M. The substantial disparity between the $1.42B revenue and the $9.66M net income highlights a challenging cost structure where operating expenses heavily impact bottom-line profitability, resulting in a profit margin of only 0.7%. Despite this, the firm generated positive free cash flow of $112.90M, which indicates robust financial flexibility to fund capital expenditures, manage working capital, or pursue strategic initiatives without relying on external financing. The gross margin stands at 32.4%, reflecting the pricing power and cost of goods sold in service-based healthcare, while the operating margin of 4.7% and profit margin of 0.7% demonstrate that overhead costs consume a significant portion of gross profits before reaching net income. On the balance sheet, the company holds $248.64M in cash against total debt of $474.52M, resulting in a debt-to-equity ratio of 31.20, which characterizes a leveraged balance sheet where liabilities exceed liquid assets. Liquidity is managed effectively with a current ratio of 1.65, indicating that current assets are 1.65 times greater than current liabilities, providing a comfortable buffer for short-term obligations. Furthermore, the return on equity is 0.7% and the return on assets is also 0.7%, metrics that reveal limited management effectiveness in generating returns relative to the capital invested and the total asset base employed.
バリュエーション評価
Valuation metrics for LifeStance Health Group, Inc. show a trailing P/E ratio of 324.50 and a forward P/E of 16.97. The extreme divergence between these two figures implies that the market expects a dramatic increase in future earnings to justify the current stock price, as the forward multiple is significantly lower than the historical trailing multiple. The price-to-book ratio is 1.66, indicating that the market values the company at a 66% premium over its book value, which suggests investors are pricing in significant growth potential or intangible assets not fully captured on the balance sheet. Alternative valuation measures include a price-to-sales ratio of 1.74 and an EV/EBITDA of 34.48, which provide context for the company's valuation relative to its sales revenue and earnings power, respectively. In terms of trading range, the stock has a 52-week high of $8.09 and a 52-week low of $3.74, with the current price situated near the lower end of this historical range relative to the peak. The beta value is 1.13, which signifies that the stock's price volatility is 13% higher than that of the broader market, reflecting increased sensitivity to market movements.
Growth & Income
Revenue growth for the company over the past year stands at 17.4%, while earnings growth is listed as N/A, indicating a period where revenue expansion has not yet translated into proportional earnings growth. This dynamic suggests that earnings are growing slower than revenue, likely due to the low profit margins and high operating leverage required to turn top-line growth into bottom-line results. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the firm retains all of its earnings for reinvestment into the business rather than distributing cash to shareholders. Consequently, the overall growth and income profile is characterized by a high-growth revenue trajectory funded by retained earnings, with no reliance on dividend income for investors.